載入中
NASDAQHealthcareMedical - Devices
最新資料
US$1.12
+US$0.04 · +3.70%
NeuroOne Medical Technologies Corporation functions as a specialized medical technology enterprise. Its core mission involves the invention and market deployment of sophisticated thin-film electrode systems. These systems are crafted for diverse neurophysiological applications, such as the continuous recording of electroencephalograms (cEEG) and stereoelectroencephalograms (sEEG), as well as therapeutic interventions including spinal cord stimulation, brain stimulation, and ablation procedures. The technology aims to assist individuals afflicted by conditions like epilepsy, Parkinson's disease, dystonia, essential tremors, persistent pain arising from unsuccessful back surgeries, and a variety of other neurological disorders. Furthermore, the company has forged a crucial partnership with RBC Medical Innovations to engineer a radio frequency ablation generator. This generator is designed to integrate seamlessly with NeuroOne's unique dual-function electrode, allowing for both the precise monitoring of brain electrical activity and the targeted ablation of brain tissue using a singular instrument. The corporate headquarters are situated in Eden Prairie, Minnesota.
前收盤價
US$1.12
+US$0.04 · +3.70%
盤中時間採用ET。市場資料可能有所延遲。
NeuroOne Medical Technologies Corporation functions as a specialized medical technology enterprise. Its core mission involves the invention and market deployment of sophisticated thin-film electrode systems. These systems are crafted for diverse neurophysiological applications, such as the continuous recording of electroencephalograms (cEEG) and stereoelectroencephalograms (sEEG), as well as therapeutic interventions including spinal cord stimulation, brain stimulation, and ablation procedures. The technology aims to assist individuals afflicted by conditions like epilepsy, Parkinson's disease, dystonia, essential tremors, persistent pain arising from unsuccessful back surgeries, and a variety of other neurological disorders. Furthermore, the company has forged a crucial partnership with RBC Medical Innovations to engineer a radio frequency ablation generator. This generator is designed to integrate seamlessly with NeuroOne's unique dual-function electrode, allowing for both the precise monitoring of brain electrical activity and the targeted ablation of brain tissue using a singular instrument. The corporate headquarters are situated in Eden Prairie, Minnesota.
日內區間
目前US$1.12
52週區間
目前US$1.12
盤中時間採用ET。市場資料可能有所延遲。
NeuroOne Medical Technologies Corporation functions as a specialized medical technology enterprise. Its core mission involves the invention and market deployment of sophisticated thin-film electrode systems. These systems are crafted for diverse neurophysiological applications, such as the continuous recording of electroencephalograms (cEEG) and stereoelectroencephalograms (sEEG), as well as therapeutic interventions including spinal cord stimulation, brain stimulation, and ablation procedures. The technology aims to assist individuals afflicted by conditions like epilepsy, Parkinson's disease, dystonia, essential tremors, persistent pain arising from unsuccessful back surgeries, and a variety of other neurological disorders. Furthermore, the company has forged a crucial partnership with RBC Medical Innovations to engineer a radio frequency ablation generator. This generator is designed to integrate seamlessly with NeuroOne's unique dual-function electrode, allowing for both the precise monitoring of brain electrical activity and the targeted ablation of brain tissue using a singular instrument. The corporate headquarters are situated in Eden Prairie, Minnesota.
日內區間
目前US$1.12
52週區間
目前US$1.12
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 1209.77萬 USD | 345.3萬 USD | 195.24萬 USD | 17.12萬 USD | 17.81萬 USD |
| 銷貨成本 | 395.63萬 USD | 237.33萬 USD | 149.59萬 USD | 24.2萬 USD | 27.59萬 USD |
| 毛利 | 814.14萬 USD | 107.97萬 USD | 45.65萬 USD | −7.08萬 USD | −9.77萬 USD |
| 研究與開發 | 498.34萬 USD | 506.52萬 USD | 694.07萬 USD | 492.94萬 USD | 392.5萬 USD |
| 銷售、一般及管理費用 | 738.45萬 USD | 790.17萬 USD | 692.63萬 USD | 697.94萬 USD | 626.03萬 USD |
| 營業費用 | 1236.79萬 USD | 1296.69萬 USD | 1241.18萬 USD | 996萬 USD | 1012.05萬 USD |
| 利息支出 | 33.41萬 USD | 22.9萬 USD | — | — | 3053 USD |
| 折舊和攤銷 | 26.17萬 USD | 24.68萬 USD | 19.93萬 USD | 11.86萬 USD | 8.07萬 USD |
| 營業利益 | −422.65萬 USD | −1188.72萬 USD | −1195.53萬 USD | −1003.08萬 USD | −1021.82萬 USD |
| 淨利 | −360.54萬 USD | −1231.81萬 USD | −1185.95萬 USD | −999.96萬 USD | −994.82萬 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$5.00
上漲空間 346.43%評級樣本有限，僅4項
| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2026年4月16日 | 1:6 | — | — |
股票分割 | 2021年4月1日 | 1:3 | — | — |
已生效 2026年4月16日
1:6
已生效 2021年4月1日
1:3
報告持有此股票曝險的交易所交易基金。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
